栗占国 简历

栗占国，主任医师，教授，博士生导师，北京大学人民医院临床免疫中心主任，医学部风湿免疫学系主任，北京大学临床免疫中心主任。

973首席科学家, 国家杰出青年基金获得者, 获吴杨医学奖和北京大学国华杰出学者奖。

中国医促会风湿免疫分会主委，中国免疫学会自身免疫分会主委，中华医学会风湿免疫分会前主委，国际风湿病联盟(ILAR)和亚太风湿病联盟(APLAR)前主席。

《 Rheumatology Autoimmunity 》主编，《中华风湿病学杂志》名誉主编。在Nat Med, Science及Lancet Rheum等发表SCI论文500余篇，入选爱思唯尔中国高被引学者。

发表文章(第一或责任作者)

1. He J, Chu Y, Li J, Meng Q, Liu Y, Jin J, Wang Y, Wang J, Huang B, Shi L, Shi X, Tian J, Zhufeng Y, Feng R, Xiao W, Gan Y, Guo J, Shao C, Su Y, Hu F, Sun X, Yu J, Kang Y, Li Z. Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis. Sci Adv. 2022;8(6): eabm1511.
2. Zhang X, Miao M, Zhang R, Liu X, Zhao X, Shao M, Liu T, Jin Y, Chen J, Liu H, Zhang X, Li Y, Zhou Y, Yang Y, Li R, Yao H, Liu Y, Li C, Li Y, Ren L, Su Y, Sun X, He J, Li Z. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. STTT. 2022;7(1): 67.
3. Sun X, Li R, Cai Y, Al-Herz A, Lahiri M, Choudhury MR, Hidayat R, Suryana BPP, Kaneko Y, Fujio K, Van Hung N, Pandya S, Pang LK, Katchamart W, Sigdel KR, Paudyal B, Narongroeknawin P, Chevaisrakul P, Sun F, Lu Y, Ho C, Yeap SS, Li Z; APLAR RA SIG group. Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. Lancet Reg Health (WP). 2021;15:100240.
4. Chen X, Sun X, Yang W, Yang B, Zhao X, Chen S, He L, Chen H, Yang C, Xiao L, Chang Z, Guo J, He J, Zhang F, Zheng F, Hu Z, Yang Z, Lou J, Zheng W, Qi H, Xu C, Zhang H, Shan H, Zhou XJ, Wang Q, Shi Y, Lai L, Li Z, Liu W. An autoimmune disease variant of IgG1 modulates B cell activation and differentiation. Science. 2018;362(6415): 700-5.
5. Mu R, Li C, Li X, Ke Y, Zhao L, Chen L, Wu R, Wu Z, Zuo X, Xie Y, Chen J, Wei W, Liu Y, Li Z, Dai L, Sun L, Liu X, Li Z. Effectiveness and safety of Iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study. Lancet Reg Health (WP). 2021; 10: 100128.
6. Hu F, Jiang X, Guo C, Li Y, Chen S, Zhang W, Du Y, Wang P, Zheng X, Fang X, Li X, Song J, Xie Y, Huang F, Xue J, Bai M, Jia Y, Liu X, Ren L, Zhang X, Guo J, Pan H, Su Y, Yi H, Ye H, Zuo D, Li J, Wu H, Wang Y, Li R, Liu L, Wang XY, Li ZG. Scavenger receptor-A is a biomarker and effector of rheumatoid arthritis: A large-scale multicenter study. Nat Commun. 2020; 11(1):1911.
7. He J, Sun X, Li Z. Low dose IL-2 for patients with systemic lupus erythematosus. The Lancet Rheumatology. 2019;1(4): e203.
8. Li Z., He J. Yu D. The rise of IL-2 therapy — a picture beyond Treg cells. Nat Rev Rheumatol. 386.
9. He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, Xu C, Hou Z, Leong YA, Zhu L, Feng J, An Y, Jia Y, Li C, Liu X, Ye H, Ren L, Li R, Yao H, Li Y, Chen S, Zhang X, Su Y, Guo J, Shen N, Morand EF, Yu D, Li Z. Low-dose interleukin-2 treatment modulates CD4+ T cell subsets selectively in patients with systemic lupus erythematosus. Nat Med. 2016; 22(9):991-3.
10. Liu Y, Mu R, Gao YP, Dong J, Zhu L, Ma Y, Li YH, Zhang HQ, Han D, Zhang Y, McInnes IB, Zhang J, Shen B, Yang G, Li ZG. A Cytomegalovirus Peptide-Specific Antibody Alters Natural Killer Cell Homeostasis and Is Shared in Several Autoimmune Diseases. Cell Host Microbe. 2016;19(3):400-8.
11. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, Sun X, Vandenberg K, Rockman S, Ding Y, Zhu L, Wei W, Wang C, Karnowski A, Belz GT, Ghali JR, Cook MC, Riminton DS, Veillette A, Schwartzberg PL, Mackay F, Brink R, Tangye SG, Vinuesa CG, Mackay CR, Li ZG, Yu D. Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺CD4⁺T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity. 2013; 39(4):770-81.
12. Wang T, Sun X, Zhao J, Zhang J, Zhu H, Li C, Gao N, Jia Y, Xu D, Huang FP, Li N, Lu L, Li ZG. Regulatory t cells in rheumatoid arthritis showed increased plasticity toward th17 but retained suppressive function in peripheral blood. Ann Rheum Dis. 2015; 74 (6):1293-1301.
13. Du Y, Su Y, He J, Yang Y, Shi Y, Cui Y, Luo C, Wu X, Liu X, Hu F, Ma X, Zheng L, Zhang J, Zuo X, Sheng Y, Wu L,Zhang X, Guo J, Li ZG. Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus and Sjögren's syndrome. Ann Rheum Dis. 2015; 74(11): 2070-5.
14. Hu F, Mu R, Zhu J, Shi L, Li Y, Liu X, Shao W, Li G, Li M, Su Y, Cohen PL, Qiu X, Li ZG. Hypoxia and hypoxia-inducible factor-1α provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis. Ann Rheum Dis. 2014; 73(5):928-36.
15. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253-61.